Neurochem: beating Alzheimer's via beta-amyloid

"Neurochem's [NRM.TO] Alzhemed has shown real promise in Phase II trials with its unique plaque-busting action. The potential of this drug has clearly made an impact on the US Alzheimer's Association, however, gaining approval may be a difficult, lengthy process for this particular drug as its action is different to anything else currently available. "